Carcinoid syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:07:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Carcinoid syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors https://clinicaltrials.eu/trial/efficacy-and-safety-study-of-paltusotine-for-adults-with-carcinoid-syndrome-due-to-well-differentiated-neuroendocrine-tumors/ Wed, 29 Apr 2026 15:06:15 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-study-of-paltusotine-for-adults-with-carcinoid-syndrome-due-to-well-differentiated-neuroendocrine-tumors/ This study investigates the effects of paltusotine compared to placebo in adults with carcinoid syndrome, a condition that occurs in some people with well-differentiated neuroendocrine tumors (NETs). Carcinoid syndrome is characterized by symptoms like flushing (sudden reddening of the skin, particularly the face) and frequent bowel movements, which occur when these tumors release certain substances into the bloodstream.

The purpose of this study is to evaluate whether paltusotine, an oral medication taken daily, can reduce the number of flushing episodes experienced by patients with carcinoid syndrome. The study will also assess whether the medication affects the frequency of bowel movements and examine its overall safety.

Participants in this study will either receive paltusotine or a placebo for 12 weeks. During this time, they will need to keep a daily record of their symptoms. Some participants who are currently taking other medications called somatostatin receptor ligands (SRLs) will need to stop those treatments before starting the study medication. Blood tests and imaging studies like CT scans or MRI may be performed to monitor the participants’ condition throughout the study.

]]> Study on the Safety and Effects of Paltusotine and Octreotide Acetate for Patients with Carcinoid Syndrome https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-paltusotine-and-octreotide-acetate-for-patients-with-carcinoid-syndrome/ Wed, 29 Apr 2026 15:00:58 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-paltusotine-and-octreotide-acetate-for-patients-with-carcinoid-syndrome/ This clinical trial is focused on studying Carcinoid Syndrome, a condition that arises from certain types of tumors called neuroendocrine tumors. These tumors can release hormones into the bloodstream, causing symptoms like flushing, diarrhea, and wheezing. The study will evaluate a new treatment called Paltusotine, which is taken as a tablet. Paltusotine is also known by its code name, CRN00808. The purpose of the study is to assess the safety and how the body processes different doses of Paltusotine in individuals with Carcinoid Syndrome.

Participants in the study will receive Paltusotine in varying doses of 40, 80, or 120 milligrams per day. The study will also involve a comparison with another treatment called Octreotide Acetate, which is a solution for injection. Octreotide Acetate is a synthetic version of a natural hormone that helps control symptoms of Carcinoid Syndrome. Some participants may receive a placebo instead of the active medication. The study will monitor participants over a period to observe any side effects and how well the medication is tolerated.

Throughout the study, participants will undergo regular check-ups, including laboratory tests and heart monitoring, to ensure their safety. The study aims to gather information on how Paltusotine affects the body and its potential as a treatment for managing symptoms of Carcinoid Syndrome. This research could provide valuable insights into new ways to help people living with this condition.

]]>